Aeolus’ Idiopathic Pulmonary Fibrosis Compound Gets Orphan Drug Status

Orphan Drug Status was recently granted to an experimental compound, AEOL 10150, under development by Aeolus Pharmaceuticals to address the need for novel treatments for idiopathic pulmonary fibrosis. AEOL 10150 is a broad-spectrum catalytic antioxidant thought to neutralize reactive nitrogen and oxygen species and, consequently, reduce inflammation, oxidative stress and subsequent…

HealthWell Foundation Opens Pulmonary Fibrosis Patient Fund

The independent, non-profit HealthWell Foundation is launching a new fund dedicated to supporting patients who suffer from pulmonary fibrosis. The main mission of the foundation is to offer financial help to underinsured people in the United States in order to improve their access to life-changing medical treatments.

Research and Markets Presents 2015 Pulmonary Fibrosis Pipeline Review

A recent report on Research and Markets covered this year’s featured companies’ Pipeline Therapeutics for the annual Pulmonary Fibrosis Review. The report details descriptions of 56 companies currently developing treatment strategies for therapeutics for Pulmonary Fibrosis. The team conducted comparative analysis of the companies’ compounds under clinical investigation at various stages, and…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums